| Hyperuricemia group(n = 23) | Normouricemia group (n = 27) | p |
---|---|---|---|
Gender (women/ men) | 21/2 | 26/1 | Â |
Age, Y | 40.17 ± 3.11 | 38.22 ± 2.36 |  |
SLE | 7 (14%) | 13 (26%) | Â |
SS | 8 (16%) | 6 (12%) | Â |
CTD | 4 (8%) | 0 | Â |
SSc | 3 (6%) | 2 (4%) | Â |
SLE/SS | 1 (2%) | 1 (2%) | Â |
MCTD | 0 | 5 (10%) | Â |
Body Mass Index, kg/m^2 | 22.0 ± 0.1 | 22.28 ± 0.71 | ns |
WHO functional class, III-IV/I-II | 15/8 | 17/10 | ns |
6MWD, m | 390.8 ± 30.85 | 404.1 ± 27.93 | ns |
UA, μmol/L | 467.0 ± 19.67 | 277.7 ± 10.02 | ns |
Creatinine, μmol/L | 63.24 ± 3.02 | 63.14 ± 5.33 | ns |
NT-pro BNP, pg/ml | 2368 ± 662.80 | 1270 ± 465.80 | ns |
Treatment with diuretics, yes/no | 5/18 | 6/21 | ns |
echocardiography | |||
 PASP, mmHg | 83.13 ± 4.93 | 74.19 ± 3.40 | ns |
 TAPSE, cm | 1.53 ± 0.11 | 2.15 ± 0.36 | ns |
right heart catheterization | |||
 Rap, mmHg | 8.13 ± 1.22 | 6.00 ± 0.91 | ns |
 mPAP, mmHg | 45.43 ± 2.41 | 45.70 ± 2.09 | ns |
 PAWP, mmHg | 8.91 ± 0.76 | 8.58 ± 0.77 | ns |
 CO, L/min | 3.75 ± 0.37 | 5.19 ± 0.51 | 0.029 |
 CI, L/min/m2 | 2.31 ± 0.24 | 3.15 ± 0.28 | 0.028 |
 PVR, Wood U | 12.77 ± 1.85 | 8.50 ± 1.93 | 0.0244 |
 SVO2, % | 57.81 ± 2.51 | 65.13 ± 1.97 | 0.029 |